» Articles » PMID: 37506723

Global HIV Control: is the Glass Half Empty or Half Full?

Abstract

The massive scale-up of HIV treatment and prevention over the past two decades has resulted in important reductions in new infections and mortality globally. Reduction in HIV incidence, however, has been unequal, with worsening epidemics in regions where the reach and scale of HIV control programmes have been insufficient, especially in eastern Europe, central Asia, the Middle East, north Africa, and Latin America where HIV epidemics are concentrated among key populations, including people who inject drugs, men who have sex with men, transgender people, and some minority racial and ethnic groups. The global state of the HIV pandemic highlights disparities in HIV control efforts and provides a roadmap for what should be done, including investment to better implement the effective HIV prevention and treatment tools that are available, but whose adoption and scale-up are not yet sufficient to get us close to an AIDS-free generation. To achieve the full potential of global HIV control, we call for urgent, evidence-informed implementation at scale of our existing and novel HIV prevention and treatment strategies in ways that are better, faster, more efficient, and cost-effective, especially in key populations and regions where the HIV pandemic continues to expand.

Citing Articles

Disruptions to HIV Prevention During Armed Conflict in Ukraine and Other Settings.

Nikitin B, Bromberg D, Ivasiy R, Madden L, Machavariani E, Dvoriak S Curr HIV/AIDS Rep. 2024; 22(1):10.

PMID: 39672977 PMC: 11823171. DOI: 10.1007/s11904-024-00716-x.


State of the ART (antiretroviral therapy): Long-acting HIV-1 therapeutics.

M Ravichandran S, McFadden W, A Snyder A, Sarafianos S Glob Health Med. 2024; 6(5):285-294.

PMID: 39483451 PMC: 11514626. DOI: 10.35772/ghm.2024.01049.


Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial.

Hsu Y, Chen C, Tseng C, Chen C, Lee T, Bair M Clin Mol Hepatol. 2024; 31(1):213-226.

PMID: 39415599 PMC: 11791594. DOI: 10.3350/cmh.2024.0640.


A qualitative dyad analysis of barriers and facilitators of antiretroviral therapy (ART) adherence among people who inject drugs (PWID) with HIV in Kazakhstan.

Neuenschwander P, Altice F, Remien R, Mergenova G, Sarsembayeva L, Rozental E AIDS Care. 2024; 37(1):151-160.

PMID: 39404196 PMC: 11682916. DOI: 10.1080/09540121.2024.2414078.


Inhibition of HIV-1 infection with curcumin conjugated PEG-citrate dendrimer; a new nano formulation.

Ebrahimi S, Sadeghizadeh M, Aghasadeghi M, Shafiee Ardestani M, Amini S, Vahabpour R BMC Complement Med Ther. 2024; 24(1):350.

PMID: 39358802 PMC: 11448447. DOI: 10.1186/s12906-024-04634-8.


References
1.
Swindells S, Andrade-Villanueva J, Richmond G, Rizzardini G, Baumgarten A, Masia M . Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression. N Engl J Med. 2020; 382(12):1112-1123. DOI: 10.1056/NEJMoa1904398. View

2.
Lee J, Crotty S . HIV vaccinology: 2021 update. Semin Immunol. 2021; 51:101470. PMC: 8463426. DOI: 10.1016/j.smim.2021.101470. View

3.
Crabtree-Ramirez B, Belaunzaran-Zamudio P, Cortes C, Morales M, Sued O, Sierra-Madero J . The HIV epidemic in Latin America: a time to reflect on the history of success and the challenges ahead. J Int AIDS Soc. 2020; 23(3):e25468. PMC: 7049674. DOI: 10.1002/jia2.25468. View

4.
Scarsi K, Swindells S . The Promise of Improved Adherence With Long-Acting Antiretroviral Therapy: What Are the Data?. J Int Assoc Provid AIDS Care. 2021; 20:23259582211009011. PMC: 8082990. DOI: 10.1177/23259582211009011. View

5.
Loevinsohn G, Kigozi G, Kagaayi J, J Wawer M, Nalugoda F, Chang L . Effectiveness of Voluntary Medical Male Circumcision for Human Immunodeficiency Virus Prevention in Rakai, Uganda. Clin Infect Dis. 2020; 73(7):e1946-e1953. PMC: 8492113. DOI: 10.1093/cid/ciaa1533. View